Navigation Links
Duska Therapeutics Obtains Standard & Poor's Listing
Date:6/26/2008

sperm motility. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements such as the lead candidate is expected to enter Phase II clinical trials later this year. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Researchers from the Southern University of ... back pain, and the acne causing P.acnes bacteria. Researchers believe ... bacteria seek out oxygen deprived location to seek shelter and ... P.acnes has the ability to live in the open joint ... spokesman for “ The best acne treatment ” explains why ...
(Date:5/20/2013)... WILMINGTON, Del. (PRWEB) May 20, 2013 ... named 14 young faculty members to its 2013 ... three years, the company will provide this outstanding ... their work in advancing basic science to meet ... is designed to help promising young and untenured ...
(Date:5/20/2013)... 2013 On 25-28 July, 2013, UPCP ... Paris - the beautiful city of lights. , According ... is revolutionizing the medical world. Understanding and integrating genetic ... hallmark of this transformation. Much of the present medical ... epidemiologic studies of large cohorts that do not take ...
(Date:5/20/2013)... Kitware, a leader in data visualization, today ... exploration of hospital costs across the United States ... recent release of “Medicare Provider Charge Data,” a dataset ... from the Centers for Medicare & Medicaid Services. , ... hospitals across the country has sparked considerable controversy; however, ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2Kitware Enables Interactive Exploration of CMS Medicare Data 2
... Corporation (NASDAQ: LIFE ) today announced it ... Conference on Tuesday, September 20 at 8:00am ET.  Greg ... present on behalf of the company. The company will ... weeks following the conference on the Life Technologies, investor ...
... Aug. 29, 2011 Chemical Abstracts Service ( CAS ... that Syngene International , an internationally reputed contract ... biotechnology company, has signed a three-year contract to provide ... award-winning chemistry research tool. SciFinder offers ...
... 26, 2011 Quantum Learning, Inc. (QLI), ... programs, and Jay Elliot, author of the book " ... announced today a licensing agreement.  Under the terms of ... training program called "Market-Leading Innovation™ (The path to Innovation ...
Cached Biology Technology:Life Technologies to Present at the UBS 2011 Global Life Sciences Conference 2Syngene Expands Ongoing Relationship with CAS to Provide SciFinder® to All Its Scientists 2Syngene Expands Ongoing Relationship with CAS to Provide SciFinder® to All Its Scientists 3Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way" 2Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way" 3
(Date:5/17/2013)... Rutgers, The State University of New Jersey, and City ... formulation called Visikol TM that effectively clears organisms ... in place of chloral hydrate, which is one of ... is tightly regulated by the Drug Enforcement Administration (DEA) ... solutions, or clearing agents, are vital for viewing organisms ...
(Date:5/17/2013)... antelope can live at elevations of 4,000-5,000m on ... in Nature Communications , investigators from Qinghai ... some genetic factors may be associated with the ... in this work will also provide implications for ... other ruminant species. , The Tibetan antelope ( ...
(Date:5/17/2013)... The Federation of American Societies for Experimental Biology ... Institutes of Health (NIH) funding trends highlighting the devastating ... critical research. The FASEB analysis follows a May 15th ... MD, PhD, who testified that the $1.6 billion cut ... is "having a substantial impact on the scientific community." ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... YORK (Dec. 19, 2007) -- Two deadly and highly infectious ... their match in a new drug developed by scientists at ... and Nipah viruses are related, newly recognized zoonotic viruses that ... larger animals -- including pigs, horses and humans. ...
... kiss you, I,ve got a cold,. But a report just published ... on an infection by shaking someone,s hand than in sharing a ... and the UK have published the first detailed report on hand ... healthcare settings. Their findings are published in the American Journal of ...
... is the first poll to reflect the discovery reported ... used to create stem cells or their near equivalents. ... than six in 10, or 63 percent, say that ... needed, 22 percent say this development means embryonic stem ...
Cached Biology News:Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports 2Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports 3If you don't want to fall ill this Christmas, then share a festive kiss but don't shake hands 2If you don't want to fall ill this Christmas, then share a festive kiss but don't shake hands 3Widespread support for nonembryonic stem cell research, VCU Life Sciences Survey shows 2
...
... is a direct antibiotic-based selection system for ... colony survival, eliminating the need for costly ... provides close to 100% accuracy in recombinant ... for robot colony picking. This cloning ...
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
... antibody raised against a partial ... Immunogen: SLC22A3 (NP_068812, 90 ... recombinant protein with GST tag. ... NM_021977 ...
Biology Products: